Last reviewed · How we verify

NE3107 — Competitive Intelligence Brief

NE3107 (NE3107) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TSPO inhibitor. Area: Neurology.

phase 3 TSPO inhibitor TSPO (translocator protein, 18 kDa) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

NE3107 (NE3107) — BioVie Inc.. NE3107 is a small-molecule inhibitor of translocator protein (TSPO) that crosses the blood-brain barrier to reduce neuroinflammation and oxidative stress in the central nervous system.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NE3107 TARGET NE3107 BioVie Inc. phase 3 TSPO inhibitor TSPO (translocator protein, 18 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TSPO inhibitor class)

  1. BioVie Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NE3107 — Competitive Intelligence Brief. https://druglandscape.com/ci/ne3107. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: